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 
Abstract— Lithium medication is the gold standard of 
treatment in Bipolar Disorder patients, preventing and reducing 
mood swings and suicidality. However, despite its effectiveness, 
it is a potentially hazardous drug requiring regular monitoring 
of blood levels to ensure toxic levels are not reached. This paper 
describes the first steps towards developing a new portable 
device that can be used by Bipolar Disorder patients to facilitate 
the analysis of lithium blood levels at home. Solutions of lithium 
carbonate have been optically fingerprinted using a high-end 
spectrophotometer. Preliminary measurements indicate that 
while the visible to near infrared region of the absorption spectra 
fall heavily within the water band, measurements in the 
Ultraviolet region show a strong distinction between different 
lithium concentrations. The optical spectra of Lithium in the 220 
nm to 230 nm region demonstrated the ability to differentiate 
between concentrations representing those found in patients.    
I. INTRODUCTION 
Bipolar disorder is a serious life-long condition, 
characterized by recurrent episodes of depressed and manic 
mood states which cause major impairment in the lives of 
those affected [1]. Bipolar disorders affects up to 2.4 
million people in the UK, 12 million in the US and 254 
million worldwide [2]. In the UK, it is estimated that the 
annual societal cost of bipolar disorder is about £2 billion 
[3].  
Lithium is the most widely used medication for treating 
bipolar disorder [4] and, although, it is highly effective at 
reducing the frequency and intensity of mood swings, it can 
be potentially dangerous. Lithium prescribed in the form of 
carbonate (Li2CO3) or citrate has a very narrow therapeutic 
range (concentrations ranging from 0.4 to 1.0 mM) with the 
upper limit being uncomfortably close to toxic levels [5]. 
The use of lithium salts can affect thyroid and kidney 
function [6]. Toxic lithium levels can cause circulatory 
collapse, kidney failure, neurological abnormalities, 
seizures, coma and even death [5, 7]. While in health 
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lithium concentrations are reasonably stable, they can 
rapidly reach toxic levels during intercurrent illness such as 
febrile conditions and dehydration or the addition of some 
drugs [8]. 
As a result, lithium requires regular on-going 
monitoring to maintain therapeutic levels and avoid 
toxicity. Determination of blood lithium levels involves 
relatively complex laboratory methods, such as flame 
photometry or ion-selective electrode analysis, which 
require withdrawal of blood samples and transport of 
samples to the laboratory [9]. It is recognised that in the UK 
lithium monitoring falls short of recommended standards. 
Furthermore, bipolar patient adherence to lithium therapy 
is “erratic” [10]. Reasons include frequent blood tests, 
which contributes to patients defaulting from treatment. 
This is associated with unacceptably high levels of relapse.  
 Currently, there is no available blood lithium level 
analyser for bipolar patients. This research proposes the 
development of a new portable non-invasive device to 
facilitate detection of changes in lithium concentrations. 
Such a device will be painless, user-friendly and could be 
used as frequently as necessary in the patients’ home. Also, 
it would put more control into the hands of the patient while 
also providing an early warning that lithium concentrations 
are drifting outside therapeutic ranges. The device will 
incorporate optical and electrical sensing technologies. In 
an attempt to develop such a technology, this paper outlines 
the first steps in optically fingerprinting lithium carbonate 
in order to determine the optical window of interest and the 
capability of optical techniques to identify the 
concentrations of lithium found in blood.   
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II. METHOD 
As a precursor to optically identifying lithium in blood 
plasma, the optical characteristics of lithium carbonate in 
solution were investigated in order to identify the 
appropriate wavelengths and optical window on which to 
focus measurements. Therefore, solutions of lithium 
carbonate in distilled water were analyzed in the 
laboratory, including solutions whose concentrations 
reflect those typically found in blood. 
In order to observe any absorption bands unique to 
Li2CO3 in solution, a reference spectrum of pure distilled 
water was taken across the effective operational range of 
the spectrophotometer (200 – 3200 nm) (Lambda1050, 
Perkin Elmer, USA).  The spectral measurements were 
repeated three times at a resolution of 1 nm, and the results 
averaged, and smoothed in UV WinLab Data Processor 
and Viewer software (Perkin Elmer Inc, USA). 
Two batches of Li2CO3 solutions were prepared in pure 
distilled water by diluting a concentrated solution down.  
The concentrated solution was prepared using a solid pure 
(99.999%) form of Li2CO3 from Acros Organics (NJ, 
USA).  As there are two Lithium ions (Li+) in one molecule 
of Li2CO3, it was only necessary to prepare the whole 
solution to half the desired concentration to achieve the 
therapeutic doses of lithium.  Unlike other lithium salts 
Li2CO3 has negative water solubility, i.e. as temperature 
increases the amount able to dissolve into the water 
decreases. All samples were prepared and tested at ambient 
temperature (21°C), where the maximum concentration 
achievable is approximately 175 mmol/L. The batches 
were prepared and classified thus:  Batch 1 – Fingerprinting concentrations.  Batch 2 – Therapeutic concentrations. 
The concentrations prepared are shown in table 1. 
 
Table 1: Li2CO3 concentrations 
Batch 1 (mmol/L) 
[effective Li+] 
Batch 2 (mmol/L) 
[effective Li+] 
5.3 [10.6] 0.1 [0.2] 
10.7 [21.4] 0.2 [0.4] 
21.3 [42.6] 0.3 [0.6] 
42.5 [85.0] 0.4 [0.8] 
- 0.5 [1.0] 
- 0.6 [1.2] 
 
Batch 1 was processed in the same way as the reference 
water spectrum (3 repeat scans, averaged and smoothed).  
A region of interest was identified from the spectrum of 
batch 1, and by applying the 2nd derivative of this region, 
using an inbuilt Savitzky-Golay algorithm, a unique 
absorption band was identified.  Batch 2 was similarly 
treated and the area under the curve of the second 
derivative was calculated.   
These results were then used to build a calibration 
function in MATLAB® (The MathWorks, USA). This was 
done by computing the area under the absorption curve of 
the second derivative in the band of interested for all three 
scans in each therapeutic concentration, and for pure water, 
which was given a lithium concentration value of 
0.0 mmol/L for referencing purposes and zero point 
calibration. 
Lastly the samples from batch 2 were re-run in the 
spectrophotometer and their concentrations calculated 
using the calibration function. 
III. RESULTS 
A full spectrum of distilled water and the Li2CO3 
concentrations of batch 1 were obtained, see figure 1.  It 
was easily observed that the primary water absorption 
bands in the infrared regions dominate, however the UV  
 
Figure 1: Full pure water spectrum with various concentrations of Li2CO3 
  
band of approximately 200 – 240 nm demonstrated a 
characteristic slope, increasing as the concentrations got 
higher. 
In the UV region of interest the 2nd derivative of batch 1 
revealed two distinct peak regions, one with a peak value 
approximately 205 – 206 nm, the second with a peak value 
at approximately 225 nm.  The first band demonstrated a 
non-linear relationship of concentration vs. the peak 
absorbance value, whereas the second band steadily 
increased with increasing concentrations.  The band was 
labeled γ, see figure 2A. 
 
Figure 2: Second derivative absorption curves (200 – 260 nm), 
Batch 1 (A), Batch 2 (B) 
 
The second derivative of the absorption curves for the 
therapeutic concentrations were observed to have less of a 
distinct peak in the γ-band, but the general trend of the 
absorbance at the peak value was still observed to increase 
with increasing concentrations, see figure 2B. 
A calibration curve with a cubic function was computed 
from the 21 data points from the scans, see figure 3.  The 
curve is given in equation 1, and has an R2 value of 0.9758. [�࢏૛��૜] = ૙. ૙ૠ૚�૜ + ૙. ૙૞૚�૛ + ૙. ૚૙ૠ� + ૙. ૛૟૟ 
 ࢝ࢎ��� � = {ሺሺ࢞ − ૙. ૙૙૙૚�ሻሻ/ሺ૙. ૙૙૙૚૛ሻ} (1) 
and where x is the area under the curve of the 2nd 
derivative of  the spectrum at each concentration of 
Li2CO3 between 220  nm and 230 nm depicted in figure 
2B. 
 
Figure 3: Calibration curve for Li2CO3 in pure water. 
 
The batch 2 was re-run, and concentration calculation 
results are shown in table 2. The ability of the 
spectroscopic method in conjunction with the calibration 
curve to determine the lithium carbonate concentration of 
solutions decreases with decreasing concentration. 
However, it can sufficiently identify the range of 
concentration. 
 










0.10 0.00004 0.08 23 
0.20 0.00015 0.23 15 
0.30 0.00018 0.25 15 
0.40 0.00029 0.44 11 
0.50 0.00030 0.47 6 
0.60 0.00033 0.59 1 
 
IV. CONCLUSION 
It has been determined that the addition of Li2CO3 to 
pure water does have a measureable contribution in the 
deep-UV absorption spectra. 
In the therapeutic range, Li2CO3 has been shown to have 
a determinable absorption band, which we have labelled 
the γ-band, as seen when the second derivative is 
calculated, and from this a calibration function was 
constructed that had a very high correlation coefficient. 
Using the calibration function to calculate the 
concentration on a re-run of batch 2, it was revealed that 
the higher concentrations could be calculated more 
reliably, with higher accuracy.  It has to be taken into 
account that a [Li2CO3] of 0.5 mM is equal to a therapeutic 
dose of 1.0 mM, due to the double-lithium ion in the 
Li2CO3 molecule. 
  
It is therefore reasonable to conclude that with the 
method of measuring Li2CO3 reported here it can be 
determined to within a 1 – 6% accuracy whether an 
unknown solution of Li2CO3 is either inside or outside the 
high-end of the therapeutic limit.  
Observations of the 2nd derivative spectra reveal an 
interesting behavior at the 200 – 220 nm region, especially 
visible when looking at the 0.4 mM curve, absorbance 
seems to jump high then fall low again at 0.5 mM.  This 
may be the result of contaminants in the solution or an 
actual optical phenomena that has been overlooked, 
however as this curve is the result of averaging it seems 
unlikely until the experiment can be re-run. 
The 210 – 220 nm region shows the possible presence of 
an isobestic point that may indicate a point where careful 
observation and computational analyses may provide a 
reference point where therapeutic concentrations of 
Li2CO3 have a common absorbance value.  Further 
experiments are needed to determine if this is the case or 
what is being seen is the result of noise or smoothing 
errors. Further investigations are planned to make an 
attempt at measuring other common medicinal lithium 
compounds in solution to help identify any characteristic 
in the absorption spectra that is solely unique to the lithium 
ions.  Different mixtures with other common salts that 
appear in blood and other bodily fluids, such as saliva or 
urine, will also be conducted to investigate the effect that 
these have on the observed absorption curves. 
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